Source: Acacia Pharma Group plc
TR-1: Standard form for notification of major holdings
TR-1: Standard form for notification of major holdings
| NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i | ||||||
| 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: | Acacia Pharma Group plc | |||||
| 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) | ||||||
| Non-UK issuer | ||||||
| 2. Reason for the notification (please mark the appropriate box or boxes with an “X”) | ||||||
| An acquisition or disposal of voting rights | X | |||||
| An acquisition or disposal of financial instruments | ||||||
| An event changing the breakdown of voting rights | ||||||
| Other (please specify)iii: | ||||||
| 3. Details of person subject to the notification obligationiv | ||||||
| Name | The Novo Nordisk Foundation | |||||
| City and country of registered office (if applicable) | Tuborg Havnevej 19, 2900 Hellerup, Denmark | |||||
| 4. Full name of shareholder(s) (if different from 3.)v | ||||||
| Name | Novo Holdings A/S | |||||
| City and country of registered office (if applicable) | Tuborg Havnevej 19, 2900 Hellerup, Denmark | |||||
| 5. Date on which the threshold was crossed or reachedvi: | 5 September 2019 | |||||
| 6. Date on which issuer notified (DD/MM/YYYY): | 6 September 2019 | |||||
| 7. Total positions of person(s) subject to the notification obligation | ||||||
| % of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights of issuervii | |||
| Resulting situation on the date on which threshold was crossed or reached | 6.92% | 6.92% | 53,442,417 | |||
| Position of previous notification (if applicable) | 7.98% | 7.98% | 53,335,420 | |||
| 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”) | ||||
| Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii | ||||
| Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary) | X | |||
| Namexv | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
| The Novo Nordisk Foundation | 6.92% | |||
| Novo Holdings A/S | 6.92% | |||
| 10. In case of proxy voting, please identify: | ||||
| Name of the proxy holder | ||||
| The number and % of voting rights held | ||||
| The date until which the voting rights will be held | ||||
| 11. Additional informationxvi | ||||
| The shares are held by Novo Holdings A/S, the holding company in the Novo Group. Novo Holdings A/S is wholly-owned by the Novo Nordisk Foundation. | ||||
| Place of completion | Hellerup, Denmark |
| Date of completion | 6 September 2019 |